Xponance LLC Has $25.07 Million Stock Position in Boston Scientific Corporation $BSX

Xponance LLC boosted its position in Boston Scientific Corporation (NYSE:BSX) by 6.0% in the 4th quarter, HoldingsChannel reports. The firm owned 262,902 shares of the medical equipment provider’s stock after acquiring an additional 14,848 shares during the period. Xponance LLC’s holdings in Boston Scientific were worth $25,068,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. Renaissance Group LLC bought a new position in Boston Scientific in the 4th quarter valued at about $28,064,000. Rathbones Group PLC raised its holdings in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares during the period. Tounjian Advisory Partners LLC bought a new position in Boston Scientific in the 4th quarter valued at about $1,477,000. Finally, Waycross Partners LLC bought a new position in shares of Boston Scientific during the fourth quarter worth approximately $2,384,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $47.22 on Friday. The company’s 50 day simple moving average is $56.68 and its 200 day simple moving average is $75.14. The stock has a market capitalization of $70.18 billion, a price-to-earnings ratio of 19.76, a price-to-earnings-growth ratio of 0.91 and a beta of 0.56. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1 year low of $46.91 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a report on Thursday, April 23rd. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Thursday, May 28th. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Finally, Bank of America lowered their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $85.92.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.